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Prolog
Financial restrictions and a stronger focus on out-
comes assessment require rational decisions regarding
the allocation of resources in the health-care system.
Such decisions are based on medical, ethical, and eco-
nomic considerations. Management of the health-care
system requires both a medical and an economic ori-
entation at the overall societal level and regarding the
selection of appropriate health-care services in hospi-
tals and ambulatory practices. The practical applica-
tion of health economic methods can be an important
tool assuring more transparency and in validating nec-
essary decisions.
The methods made available by health economic
research represent a rational approach for a structured
resource allocation in the health-care system and facili-
tate the process of a relative assessment of various
treatment methods with each other. Although the focus
of such studies frequently rests on pharmaceuticals,
health economic evaluation methods are suitable for
all medical services, procedures, and health-care pro-
grams. But, what is assessed from which perspective,
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the selection of instruments and under which objec-
tives depends on the decision-maker for whom the
evaluation is conducted as a decision-making aid and
the normative requirements stipulated by that particu-
lar decision-maker. It is not the objective of health
economic studies to make decisions based on the
results of the speciﬁc study situation but to make value
judgments and assessment criteria of the decision-
maker transparent and to make his or her decision and
the underlying decision process easier.
All beneﬁt parameters that are relevant for the study
situation in question should be incorporated in the
assessment. It may be that data from various sources
must be taken into account, which can be accom-
plished with the help of models. Possible essential data
sources include medical meta-analyses, randomized
clinical studies, as well as epidemiological observa-
tional data on the disease or long-term impacts of
the disease. Additional relevant sources are cohort
studies, data from health-care services research, data
on current therapy standards, and possibly also expert
opinions wherever other evidence is not available.
Furthermore, the various dimensions of a treatment
beneﬁt should be addressed by collecting and assessing
data on the efﬁcacy, tolerability, quality of life, patient
satisfaction, beneﬁt of compliance, or ability to work.
The goal of the health economic analysis is the assess-
ment of beneﬁts of a new treatment compared to
an alternative treatment (effectiveness); for decisions
regarding coverage packages of health insurance
funds, the comparison to standard treatment in every-
day clinical practice is frequently chosen. The study
form to be chosen depends on the beneﬁts of interest
and the way those are supposed to be linked to costs
(e.g., cost comparison analysis, cost-effectiveness
study, cost-utility analysis). A cost–beneﬁt analysis can
be appropriate, if it is methodologically ensured that
all beneﬁt dimensions are covered in the analysis.
The “Hanover Consensus” provides a health eco-
nomic “construction kit” that aims at making the
development process of health economic studies easier
and to standardize studies in terms of applied methods.
It was ﬁrst published in 1996 and revised for the ﬁrst
time in 1999. The endorsing individuals from aca-
demia and health-care practice support it overall and
in person. In doing so, they do not express the poten-
tial position of the institution with which they are
professionally associated.
This guideline for health economic evaluation is
supposed to represent the framework for conducting
health economic evaluation studies in Germany. Devia-
tions from this guideline seem possible but should be
justiﬁed. Hence, the “Hanover Consensus” is meant to
provide standards on the one hand and to promote
methodological progress and scientiﬁc innovation in
health economics on the other. For this purpose, sci-
entiﬁc freedom is indispensable, which is explicitly
acknowledged by the consensus group. With this in
mind, rules or policies in this guideline are only stipu-
lated for those items that are theoretically and practi-
cally considered indispensable minimum requirements
for evaluations which are already reﬂected by and an
integral part of high-quality studies today. In the
future, this health economic consensus group will be
an open task force coming from academia and practice
and will continue (if needed) to regularly develop
recommendations on health economic evaluation
research.
Study Design
A health economic study should be conceptualized and
structured in concordance with scientiﬁc standards.
This includes the explicit statement of the objective,
the derivation of the hypotheses, the description of the
methodology, a justiﬁcation of the alternatives to be
evaluated, as well as the deﬁnition of the perspective
and the target population. With regard to the last
variable, it must be stated in which patient (or study)
groups the data in question were collected and to
which patient groups the outcomes are supposed to
apply. A study protocol on medical, economic, and
statistical questions and procedures must be prepared
before commencing a study. In each case regarding
health-care supply, the most realistic study design
should be chosen and implemented.
In contrast to clinical studies that are typically
designed with regard to a “Proof of Concept” concern-
ing, e.g., the clinical mode of action of a speciﬁc sub-
stance, economic evaluations are based on modeled
assumptions or ideas. These allow the illustration of
questions related to fairness, distribution, or allocation
issues in the provision of health-care services that are
of particular interest to decision-makers. To address
these issues and to enable the combination of various
different data sets, the selection of an appropriate
study form frequently requires health economic mod-
eling. Through that approach, results and statements
for longer time horizons and also the impact of the
variation of parameters on the results can be enabled
and tested.
Distributive and ethical problems and issues can be
incorporated in the study if this is required by the
primary study objective and justiﬁed by available data-
bases and relevant literature. In any case, the distribu-
tion premises must be indicated explicitly. The existing
health-care provision, organization, and allocation are
also based on value judgments, so that any status quo
is not neutral in its value judgments.
Perspective
The perspective describes the point of view from which
costs and beneﬁts are collected and assessed. Depend-
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ing on the objective of the study, various perspectives
can be meaningful in cost assessments (e.g., perspective
of the overall social security system, the health-care
system as part of the latter, the health insurance funds,
hospitals, physicians, or patients). If possible, when
considering individual components of the costs and
beneﬁts, it should be ensured that the perspective is
synchronized in both outcome dimensions. Priority
should be given to the societal perspective. Legitimate
deviations from that must be justiﬁed in detail based
on the decision-making situation in question. The
choice of perspective per se must be justiﬁed and logi-
cally elaborated from the decision problem. If several
perspectives are taken into account in one study, the
assumptions and results must be separately indicated
for each study perspective.
Study Forms
Health economic studies can be classiﬁed with regard
to the type of variables that are assessed and according
to their analytical approach. The choice of the type of
analysis depends on the study subject as well as the
purpose of the study, and must be justiﬁed accordingly.
Complete health economic evaluation studies, espe-
cially cost-effectiveness and cost-utility studies, aim at
comparing costs and consequences of various mea-
sures. Cost–beneﬁt analyses are appropriate when the
methodological issues regarding the transformation of
intangible effects into monetary units are sufﬁciently
addressed. Over the past few years, comprehensive
research has been conducted in this area, allowing the
use of these study forms if sufﬁcient substantiation in
the literature from a methodological and scientiﬁc
point of view can be demonstrated.
The cost-of-illness analysis should be mentioned as
an additional study form. Cost-of-illness studies are
meant to provide information on the frequency of
speciﬁc diseases, the types of relevant therapies, the
frequency and costs of different therapies, and other
general issues or facets of the illness in question. This
study form has a special importance in the assessment
of the economic relevance of a disease to society. As
part of cost-of-illness analyses, descriptive cost com-
parison analyses looking at deﬁned disease subgroups
can also be conducted.
When conducting the study, the relevant current
state of the art guidelines (especially Good Clinical
Practice (GCP) for randomized clinical studies, Good
Epidemiological Practice, and the recommendations of
the Cochrane Group) should be applied. For all study
forms, the literature research itself, the assessment of
the cited literature, the modeling algorithms and cal-
culations, as well as the computer programs used
should be documented thoroughly, and the underlying
assumptions clearly justiﬁed.
If the available cost and efﬁcacy or effectiveness
data do not consist of sufﬁcient external validity,
because current health-care practice is insufﬁciently
represented, health economic modeling via decision-
analytical methods can be conducted. For this purpose,
all data sources used and the structural and quantita-
tive assumptions made must be disclosed, the model
structure must be justiﬁed in detail, and its robustness
must be thoroughly tested through sensitivity analyses.
In addition, the software program to conduct the mod-
eling must be indicated. If intermediate or surrogate
outcome parameters are used to estimate effectiveness,
their effect on patient-relevant outcome parameters
such as mortality, morbidity, and the burden of treat-
ment must be demonstrated based on scientiﬁc evi-
dence. The modeling results should be veriﬁed in
practical health-care services research studies (e.g.,
cohort studies, pragmatic clinical studies, registries) as
soon as possible.
Selection of Alternatives
The objective of a health economic evaluation is the
disease-speciﬁc comparison of a speciﬁc therapy with
alternative courses of action. The comparison should
be made in light of a complete description of relevant
treatment pathways within the health-care system. The
study may compare the approach in question with the
most frequent, the most clinically effective, or the most
efﬁcient alternative or pathway. In doing so, the alter-
native of nontreatment may also be considered. The
choice of reference alternative(s) must be justiﬁed.
Validity and Data Sources
Data sources for health economic evaluation studies
include information on the medical efﬁcacy or effec-
tiveness of certain alternatives, as well as information
on the economic consequences of each alternative. In
addition, economical, medical, and epidemiological
frameworks of health-care provision should be taken
into account. All data sources used in a health eco-
nomic evaluation must be described in detail, and their
selection with regard to the study objective as well as
the perspective must be justiﬁed and assessed in terms
of their suitability and their internal and external
validity. Clinical studies generally have high internal
validity which may be accompanied by low external
validity. In such a case, such studies should be supple-
mented by high-quality health economic studies with
greater external validity.
The comparative quantiﬁcation of the effectiveness
of treatment alternatives requires studies that have a
scientiﬁc design comparable to the designs in random-
ized, controlled studies. As a prerequisite for economic
considerations in a speciﬁc case, clinical studies evalu-
ating medical efﬁcacy are indispensable. Nevertheless,
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as mentioned before, clinical studies often cannot serve
as the sole basis of information for a health economic
assessment. A realistic estimate of the costs can be
limited under study conditions, if the use of some
health-care services only arises from the study plan. In
addition, clinical studies mostly cover only a brief
period of time, the indication is narrowed down, and
populations in terms of inclusion and exclusion criteria
(e.g., complications and age) are strongly selected. Fur-
thermore, studies are mainly statistically powered to
investigate the medical efﬁcacy of a speciﬁc treatment
and therefore the study sample is too small to be able
to reﬂect rare events with serious economic conse-
quences. Hence, in many cases, models, for which
requirements are described in the “Study forms”
section, can achieve better external validity. When
expert opinions are included in such studies, the selec-
tion criteria of the panel and the process of forming
consensus must be disclosed and described in detail.
Cost Determination
In principle, all relevant costs and outcome variables
for the selected perspective must be taken into
account. Reported direct costs should cover all
resources used (capital and administration costs may
also be included, depending on the chosen perspec-
tive) that are associated with the medical treatment.
Direct medical costs are directly incurred by the
treatment process itself (e.g., costs of pharmaceuti-
cals). Direct nonmedical costs include all resources
used as a consequence of the therapy or illness (e.g.,
transportation costs, costs in the educational system,
or direct costs for household help required as a con-
sequence of the illness). From a societal perspective,
in particular partial areas of health care, e.g., infor-
mal or formal care for individuals in need of help,
the burden to caregivers may be an area of interest in
determining costs. If that burden can be transformed
and valued in monetary terms (e.g., giving up one’s
job to care for an individual), it must be taken into
account. If the valuation in monetary terms justiﬁably
cannot be conducted, such use of resources should at
least be listed quantitatively.
Generally, the use of resources must be reported
separately from prices in quantitative units. Ideally, the
valuation of direct and indirect usage of resources in
monetary terms is made with the help of opportunity
costs. With this approach, one can determine what
beneﬁt the used resources would have achieved in the
next best alternative. As a result, resource consump-
tion should be priced at market procurement prices. If
this is not possible, administered prices (e.g., remu-
neration schemes from the statutory insurance) and
average values also can be used.
A marginal analysis should be performed to quan-
tify the costs and outcomes of an additionally pro-
duced unit. Averages should only be used, if marginal
values are unavailable. In this case, the use of average
prices must be pointed out explicitly.
When interpreting the costs, an overestimation of
costs due to components not fully attributable to the
disease must be avoided. For a study taking the societal
perspective, existing inefﬁciencies in the system and
their cost-effects also should be listed and discussed
separately. If the intervention to be analyzed has an
impact on comorbidities associated with the indica-
tion, these should be included in the analysis, if this
is relevant from the selected study perspective. Any
resulting data must also be reported separately and
discussed with regard to effects.
Indirect costs comprise all other costs caused indi-
rectly through the treatment or the illness, including
sick leave days at work. Apart from losses based on
absence from work, the reduction in the ability to
perform (at the respective work) can be reported sepa-
rately. As for its relative importance, the latter has a
more informative character, because resulting welfare
losses are methodologically difﬁcult to collect. None-
theless, these speciﬁc productivity losses may be more
relevant under certain study perspectives, but this must
be separately justiﬁed and discussed.
As no full employment exists in industrialized coun-
tries, open positions can typically be reﬁlled within a
relatively short period of time. One way to account for
this fact is to only assess the time frame up until a
worker has been replaced (friction period) as a loss in
productivity (e.g., early retirement due to the illness).
Short-term productivity losses must be assessed more
cautiously. Typically relevant job duties are at least
partially performed by other employees during the
individual’s illness or by the individuals themselves
after their return to work.
The value of the productivity losses is the work
time lost through illness multiplied by the market
value of this work time, e.g., represented by the wage
costs per time unit from the perspective of the
employer (i.e., wages plus premiums to social insur-
ance schemes payable by the employer). The chosen
approach of calculation must be presented and justi-
ﬁed in detail for all used reference groups (e.g., if
there are differences according to age or sex). Fur-
thermore, as a reference, the results should be recal-
culated taking the value of a lost work day using the
terms “overall employees” compensation in Germany
per year (including social insurance premiums)
divided by “number of employees times 365.” The
nomenclature used in this formula corresponds to the
wording from the ofﬁcial statistics of the Federal Sta-
tistical Ofﬁce. By using the ofﬁcial ﬁgures from 2006,
one obtains a rounded value of €90 per lost day of
work. Naturally, this example changes over the
course of time, which is why this amount has to be
adjusted continuously.
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Deviations from that formula should be discussed
and justiﬁed. With this approach, sick leave days
falling on Sundays and holidays must also be consid-
ered. The average productivity loss resulting from the
above-described calculations is also used for self-
employed individuals. Depending on the perspective,
transfer payments may also be taken into account, but
attention must be paid to the risk of double counting.
Collection of Outcome Parameters
The suitability of outcome parameters depends on
both the disease and the study question of the eco-
nomic evaluation. Within a study setting, mortality-
and morbidity-related parameters as well as clinical,
nonintermediate states, quality of life-related out-
comes, and other parameters can be used. The selec-
tion of outcome parameters must be justiﬁed.
The subsequent assessment of study results is
made easier by choosing outcome parameters that
have already been validated in the literature and are
accepted for that indication. Guidelines and recom-
mendations of the relevant medical specialists’
group(s) should be considered. If no such instruments
or outcome parameters are commonly accepted or
available within that speciﬁc specialists’ group, the
choice must also be justiﬁed in detail.
When applying cost-effectiveness and cost-utility
analyses, the selection of outcome parameters is of key
importance. If utility values (e.g., quality-adjusted life-
years [QALYs]) are included in a study, these should
be preferably determined through direct generation
of individual values via standard gamble, the time-
trade-off method, or with validated, preference-based,
generic instruments (e.g., EQ-5D or SF-6D). The vali-
dation and preferences of these questionnaires should
be based on a representative population sample from
Germany. In speciﬁc study situations the application of
a visual analog scale (VAS) can also be appropriate, if
the validity of the information can be justiﬁed. In
well-substantiated exceptions, it is acceptable to
deviate from population-based preference values.
Time Horizon
The selection of the time horizon depends on the study
subject and can range from just a few weeks to a
lifelong time period for chronic diseases or preventive
services. In any case, the entire time span, during
which an impact of a study alternative on resource
usage, effectiveness, outcomes, utilities, or quality of
life can be expected or has been substantiated by pre-
vious research data, must be analyzed. Models are
often required because of the fact that, at the time a
health economic assessment is conducted, no compre-
hensive data have been generated in most cases to
cover relevant time horizons (e.g., data on effects of a
therapy after the conclusion of clinical trials). Based on
the study subject, several relevant time points should
be set for the cost-effectiveness calculations (if this
study form is selected).
Discounting
If costs and/or health effects (outcomes) are accrued
for more than 1 year, the calculation of present values
is necessary to ensure comparability of payment ﬂows
and the associated beneﬁt. An annual reference dis-
counting rate must be set at 5%, and the robustness of
the outcomes should be checked with higher and lower
discounting rates (0%, 3%, 10%) as part of the
sensitivity analyses. The discounting rate for costs
and health effects (e.g., QALYs) should be chosen
identically. Deviations must be specially justiﬁed and
checked in sensitivity analyses.
Sensitivity Analyses
All outcomes must be checked for their reliability
(robustness) and their dependence on individual input
parameters used (costs and beneﬁts).
In all cases, the inﬂuence of individual parameters
must be analyzed via a univariate approach. For this
purpose, the individual input parameters are varied
within a range, which may be based on realistic con-
siderations or a schematic variation (e.g., variation by
percentages).
If possible, the robustness should be analyzed as
part of a probabilistic approach, with each input
parameter being included according to its speciﬁc dis-
tribution, which should be based on empirically deter-
mined values including their dispersion. A distribution
can be assigned to missing data, but that has to be
justiﬁed in detail. Alternatively, a different multivariate
approach can be chosen that varies multiple param-
eters simultaneously during the analysis.
Independent of the selected method for the sensitiv-
ity analysis, the variation range must be discussed and
justiﬁed in each case. Furthermore, it is recommended
to develop and discuss hypothetical worst-case and
best-guess scenarios. The results of the sensitivity
analyses must be critically discussed and assessed in
terms of their stability and ethical implications.
Presentation and Discussion of Outcomes
All outcomes must be reported with the relevant
statistical measures of dispersion. In addition, the
outcomes must be discussed with regard to their gen-
eralizability outside the chosen study setting and set in
reference to previously known and published data.
Furthermore, all previously deﬁned research questions
should be answered and addressed with the help of the
study results. Discussion of the outcomes must always
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be made in light of the German health-care context as
well as the chosen perspective. As part of the conclud-
ing discussion, the key limitations and uncertainties of
the outcomes and methods must be indicated and criti-
cally addressed. Moreover, relevant key conclusions
and recommendations for decision-makers should be
stated.
Publication of Outcomes
Health economic studies must be transparent. As a
result, their quality also depends on the extent of their
publicity and availability. Study results should be pub-
lished in journals that have a peer review policy prior
to publication. Choosing not only health economic
journals but also scientiﬁc journals of the respective
medical ﬁeld is appropriate. For methodologically
complex studies, it is advantageous to generate a
detailed methodological documentation in addition to
the publication that can be made available on request.
Signiﬁcant outcomes should be presented in aggre-
gated and disaggregated form. The authors must
ensure (e.g., with technical appendices) that the out-
comes of complex studies (e.g., comprehensive model-
ing studies) can be followed by an expert third party.
The results of the study must be compared to the
results of other studies with a similar study question.
Methodological differences and different study condi-
tions should be pointed out and addressed in detail,
because different study conditions and populations
may contribute to different outcomes. If possible, the
potential relevance and consequences of the study
results should also be stated for decision-makers.
In accordance with existing policies for clinical
trials, the study should be published independent of
the results. Conﬂicts of interest must be stated in the
publication.
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